|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Biliary acute pancreatitis:a review显示文摘INTRODUCTIONIt is axiomatic that the most effective and soundlybased plan of treatment of any disorder is one aimedat the mechanism or mechanisms responsible for itsdevelopment.This basic notion,coupled withrecent reports in which,surprisingly there is atotal lack of reference to the probable involvementof autonomic-arc-reflexes in the | Osvaldo M.Tiscomia Susana Hamamura Enriqueta S.deLehmann Graciela Otero Hipolito Waisman Patricia Tiscornia-Wasserman Simmy Bank | 2000 | World Journal of Gastroenterology2000，6，2： | 6 |
| 2 | Crohn's disease and risk of fracture: does thyroid disease play a role?显示文摘AIM: To assess the role of thyroid disease as a risk for fractures in Crohn's patients.METHODS: A cross-sectional study was conducted from 1998 to 2000. The study group consisted of 210 patients with Crohn's disease. A group of 206 patients without inflammatory bowel disease served as controls. Primary outcome was thyroid disorder. Secondary outcomes included use of steroids, immunosuppressive medications, surgery and incidence of fracture.RESULTS: The prevalence of hyperthyroidism was similar in both groups. However, the prevalence of hypothyroidism was lower in Crohn's patients (3.8 % vs 8.2 %, P=0.05).Within the Crohn's group, the use of immunosuppressive agents (0 % vs11 %), steroid usage (12.5 % vs37 %), small bowel surgery (12.5 % vs 28 %) and large bowel surgery (12.5 % vs27 %) were lower in the hypothyroid subset as compared to the euthyroid subset. Seven (3.4 %) Crohn'spatients suffered fracture, all of whom were euthyroid.CONCLUSION: Thyroid disorder was not found to be associated with Crohn's disease and was not found to increase the risk for fractures. Therefore, screening for thyroid disease is not a necessary component in the management of Crohn's disease. | Nakechand Pooran Pankaj Singh Simmy Bank | 2003 | World Journal of Gastroenterology2003，9，3： | 2 |
| 3 | Cytokines (IL-6, IL-8, TNF): Early and Reliable Predictors of Severe Acute Pancreatitis显示文摘 | Nakechand Pooran Anant Indaram Pankaj Singh Simmy Bank | 2003 | Journal of Clinical Gastroenterology2003，，3： | 1 |
| 4 | Multicenter, randomized, controlled trial of virtual-reality simulator training in acquisition of competency in colonoscopy显示文摘 | Jonathan Cohen Seth A. Cohen Kinjal C. Vora Xiaonan Xue J. Steven Burdick Simmy Bank Edmund J. Bini Henry Bodenheimer Maurice Cerulli Hans Gerdes David Greenwald Frank Gress Irwin Grosman Robert Hawes Gerard Mullen Felice Schnoll-Sussman Anthony Starpoli | 2006 | Gastrointestinal Endoscopy2006，，3： | 1 |
| 5 | Hyperamylasemia in Inflammatory Bowel Disease显示文摘 | Seymour Katz Simmy Bank Ronald E. Greenberg Sarolta Lendvai Martin Lesser Barbara Napolitano | 1988 | Journal of Clinical Gastroenterology1988，，： | 1 |
| 6 | Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia显示文摘AIM To evaluate the long-term safety ofomeprazole in patients of gastroesophagealreflux disease resistant to treatment with H2receptor antagonist.METHODS We prospectively followed 33patients on omeprazole therapy for severeerosive esophagitis for 5-8 years,with periodicgastrin levels,H.pylori infection,gastricbiopsies for incidence of ECL cell hyperplasia,carcinoids,gastric atrophy and neoplasia.Atotal 185 patient follow-up years and 137 gastricbiopsies were done.RESULTS Among the 33 patients,36% reachedtheir peak gastrin levels in an average of 8months to one year,then drifted Down slowlyover 1-2 year period to just above their baselinelevel,24% of the patients had a peak gastrinlevel above 400ng·L^1 and one patient had apeak level above 1000 ng·L^1.One patient had amild ECL cell hyperplasia which was self limitingand did not show any dysplastic changes.Eighteen percent of patients were positive forH.pylori infection.The gastric biopsies did notshow gastric atrophy,intestinal metaplasia orneoplastic changes.CONCLUSION In a series of 33 patients followed for 5 - 8 years on omeprazole therapy for severe reflux esophagitis, we did not observe any evidence of significant ECL cell hyperplasia, gastric atrophy, intestinal metaplasia, dysplasia or neoplastic changes. | Pankaj Singh Anant Indaram Ronald Greenberg Vernu Visvalingam Simmy Bank | 2000 | World Journal of Gastroenterology2000，6，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员